Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Reva Medical looks to CE Mark for Fantom scaffold
Reva Medical said today it completed its submission for CE Mark approval of its Fantom sirolimus-eluting bioresorbable coronary scaffold following the completion of a clinical data analysis and testing.
The San Diego, Calif.-based company said it is hopeful it will receive CE Mark approval by December 31, 2016. Read more
4. Wright Medical surges on Street-beating Q2
Wright Medical saw shares surge over 10% after releasing 2nd quarter earnings that topped the Street in earnings per share but were off on revenue.
The Memphis, Tenn.-based company reported losses of $229.4 million, or $2.23 per share, on sales of $170.7 million for the 3 months ended June 26. Read more
3. LivaNova posts beat-and-raise Q2
LivaNova today posted Street-beating 2nd quarter earnings, raising its guidance and seeing shares rise over 10%.
The U.K.-based company reported profits of $9 million, or 18¢ per share, on sales of $321 million for the 3 months ended June 30. Read more
2. ReliantHeart wins CE Mark for aVAD left ventricular assist device
ReliantHeart said yesterday it won CE Mark approval in the European Union for its aVAD left ventricular assist device.
The aVAD device is an axial flow LVAD that features remote monitoring and flow measurement, according to an MD+DI report. Read more
1. DexCom shares droop on Q2 release
Dexcom Inc. released its 2nd quarter earnings late yesterday, nailing Wall Street analysts expectations for revenue but missing on earnings per share by nearly double, seeing shares shrink in response.
The San Diego, Calif.-based company reported losses of $20.2 million, or 24¢ per share, on sales of $137.3 million for the 3 months ended June 30. That amounts to a massive 445% increase in losses on the bottom end while sales swelled 47.8% compared with the same period from the prior year. Read more
